Clinical trials: Control Subjects
Atopic Dermatitis
Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis
This is a phase II, double blind study with ZEP-3NA 0.1% or 1% vs. vehicle-control in subjects with mild to moderate Atopic Dermatitis.
- Trial name
- NCT04307862
- Testing
- ZEP-3Na 0.1%, ZEP-3Na 1%
- Where
- 10 sites in Israel
- Volunteers
- 165 people
- Sponsor
- Shulov Innovate for Science Ltd. 2012
Type 2 Diabetes Mellitus
Extension Study for 2993-112
This multicenter, open-label extension study of Protocol 2993-112 is designed to assess long-term glucose control as measured by HbA1c (glycosylated hemoglobin) and to evaluate long-term safety and tolerability in subjects…
- Trial name
- NCT01789957
- Testing
- AC2993
- Where
- 226 sites in United States, Canada
- Volunteers
- 225 people
- Sponsor
- AstraZeneca
Alopecia Areata
PF-06651600 for the Treatment of Alopecia Areata
This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss.
- Trial name
- ALLEGRO-2b/3 (NCT03732807)
- Testing
- PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2
- Where
- 155 sites in United States, Argentina and 16 more
- Volunteers
- 718 people
- Sponsor
- Pfizer
Neisseria Meningitides Meningitis
A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years
This is a phase IV, single-center, observer-blind, randomized, controlled vaccine trial in 2 to 10 years old healthy subjects. Each participant will receive a single intramuscular injection of one of the two vaccines either MPV…
- Trial name
- NCT04450498
- Testing
- Yuxi Walvax MPV ACYW® vaccine, Sanofi Pasteur Menactra® vaccine
- Where
- Mali
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
Dystrophic Epidermolysis Bullosa
Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa
After confirming eligibility, a single subject with four selected target lesions will receive both ALLO-ASC-SHEET and Vehicle control, three target lesions for ALLO-ASC-SHEET and the other target for Vehicle control, and which…
- Trial name
- NCT05157958
- Testing
- ALLO-ASC-SHEET, Vehicle Control
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Anterogen Co., Ltd.
Eosinophilic Esophagitis
Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis
Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus, characterized by eosinophilic infiltration and gastrointestinal (GI) symptoms.
- Trial name
- NCT01386112
- Testing
- EUR-1100
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Forest Laboratories
Atopic Dermatitis
Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis
This Phase 2 study will assess efficacy, safety, and tolerability of TER-101 ointment and vehicle twice daily for 28 days in adult and adolescent subjects with mild to moderate atopic dermatitis.
- Trial name
- NCT04753034
- Testing
- TER-101, Vehicle
- Where
- 12 sites in United States
- Volunteers
- 63 people
- Sponsor
- Teres Bio, Inc.
Excessive Bleeding During Surgery
A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants
The objective of the study is to evaluate if FS Grifols is non-inferior to EVICEL® in terms of the percentage of participants achieving hemostasis at the target bleeding site (TBS) by 4 minutes (T4) from the start of treatment…
- Trial name
- NCT03461406
- Testing
- Fibrin Sealant Grifols, EVICEL
- Where
- 40 sites in United States, Bulgaria and 8 more
- Volunteers
- 186 people
- Sponsor
- Instituto Grifols, S.A.
Thrombosis
Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure
The Purpose of this study is to characterize the single and multiple-dose pharmacokinetic (PK) and pharmacokinetic/pharmacodynamic (PK/ PD) profiles after oral rivaroxaban therapy administered to pediatric participants 2 to 8…
- Trial name
- UNIVERSE (NCT02846532)
- Testing
- Rivaroxaban, Acetylsalicylic Acid
- Where
- 42 sites in United States, Argentina and 8 more
- Volunteers
- 112 people
- Sponsor
- Janssen Research & Development, LLC
Eosinophilic Esophagitis
A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021
This purpose of this study is the long-term follow-up of glucocorticosteroid-related adverse events and hypothalamic-pituitary-adrenal axis (HPA) suppression in subjects after discontinuation of study drug received in the PR-021…
- Trial name
- NCT01498497
- Testing
- EUR-1100
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Forest Laboratories
Ankle Sprain
FS-67 in the Treatment of Pediatric Patients With Ankle Sprain
The objective of this study is assess the efficacy and safety of single and multiple applications of the FS-67 patch in the treatment of ankle sprain in pediatric population (ages 13-17).
- Trial name
- NCT01037816
- Testing
- FS-67 Patch
- Where
- 23 sites in United States
- Volunteers
- 252 people
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
Acne Vulgaris
Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients
This is a multicenter, randomized, double-blind, placebo-controlled, 3-arm, parallel-group, ambulatory safety and efficacy study of ARK-E021 topical foam of 5% and 10% in subjects with mild to moderate acne vulgaris.
- Trial name
- NCT01494285
- Testing
- ARK-E021 5%, ARK-E021 10%
- Where
- 3 sites in Israel
- Volunteers
- 157 people
- Sponsor
- M. Arkin 1999 Ltd.
Dravet Syndrome (DS)
A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome
The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of convulsive seizures in children and young adults with DS.
- Trial name
- NCT04940624
- Testing
- Soticlestat
- Where
- 66 sites in United States, Australia and 16 more
- Volunteers
- 144 people
- Sponsor
- Takeda
Axillary Hyperhidrosis
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- CARDIGANII (NCT03948646)
- Testing
- Sofpironium Bromide, 15%, Vehicle
- Where
- 42 sites in United States
- Volunteers
- 351 people
- Sponsor
- Botanix Pharmaceuticals
Perennial Allergic Rhinitis
Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis
To demonstrate the effects of ciclesonide applied as a nasal aerosol and ciclesonide aqueous (AQ) nasal spray on hypothalamic-pituitary-adrenal axis.
- Trial name
- NCT01033825
- Testing
- Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, Ciclesonide Aqueous Nasal Spray 200 mcg
- Where
- 6 sites in United States
- Volunteers
- 310 people
- Sponsor
- Sumitomo Pharma America, Inc.
Retinitis Pigmentosa, Usher Syndrome Type 2
Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)
The purpose of this study is to evaluate the efficacy safety and tolerability of QR-421a administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene with…
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease
- Trial name
- NCT05176717
- Testing
- QR-421a
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Laboratoires Thea
Seasonal Influenza
Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)
The purpose of this study is to evaluate the safety and immunogenicity of quadrivalent influenza vaccine in healthy children aged 6-35 months.
- Trial name
- NCT03859141
- Testing
- Quadrivalent influenza vaccine, Trivalent influenza vaccine (contains B/Victoria strain), Trivalent influenza vaccine (contains B/Yamagata strain)
- Where
- 2 sites in China
- Volunteers
- 2,340 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Thrombotic Thrombocytopenic Purpura (TTP)
A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)
Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body.
- Trial name
- NCT03393975
- Testing
- TAK-755, Standard of care
- Where
- 33 sites in United States, Austria and 7 more
- Volunteers
- 52 people
- Sponsor
- Baxalta now part of Shire
Respiratory Syncytial Virus (RSV)
A Study to Evaluate EDP 938 Regimens in Children With RSV
A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.
- Trial name
- RSVPEDs (NCT04816721)
- Testing
- EDP-938
- Where
- 78 sites in United States, Argentina and 13 more
- Volunteers
- 99 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Seasonal Allergic Rhinitis
Safety and Efficacy Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis (P08648)
The purpose of this study is to determine the safety and efficacy of epinastine nasal spray compared to placebo for the treatment of subjects with seasonal allergic rhinitis
- Trial name
- NCT00564421
- Testing
- epinastine nasal spray, low concentration, low dose volume, epinastine nasal spray, low concentration, high dose volume, epinastine nasal spray, high concentration, low dose volume
- Volunteers
- 798 people
- Sponsor
- Merck Sharp & Dohme LLC